To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
Not yet recruiting · Phase 3 · NCT07116473
Conditions: Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial, Amyloid Cardiomyopathy, Amyloid Cardiomyopathy, Transthyretin-Related, Amyloidogenic Transthyretin (ATTR) Amyloidosis, Heart Disease, Cardiomyopathies, Amyloidosis, Hereditary, Transthyretin-Related, Polyneuropathies, Amyloidosis
At a glance
- Research payments reported, 2025
- $23,525
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 250
About the trial
- Sponsor
- Eidos Therapeutics, a BridgeBio company
- Tested
- Acoramidis (AG10) (drug)
- Dates
- Started 2026-11; completion 2037-12
- Results posted
- Not yet
The AG10-504 study is an open-label extension study of acoramidis in participants with newly diagnosed transthyretin amyloid cardiomyopathy (ATTR-CM) or both ATTR-CM and transthyretin amyloid polyneuropathy (ATTR-PN).
From ClinicalTrials.gov, last updated 2026-08-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eidos Therapeutics, Inc. reported $23,525 in research payments for this study in 2025 (2 payments).
Products named: Attruby
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Duke University $23,525
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.